ACS Medicinal Chemistry Letters · 2014 · 42 citations · 19 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryStructure-activity RelationshipsConformational AnalysisConformational RestrictionGabaergic PharmacologyGabaergic SignalingLigand BindingTransporter PharmacologyBioactive Conformation SelectionGaba Transporter FunctionGabaergic Drug DiscoveryGabaergic Neurotransmission Modulation
On the basis of the three-dimensional diversity-oriented conformational restriction strategy using key chiral cyclopropane units, we previously identified 3 ((2S,3R)-4-amino-3,4-methanobutyric acid) with a chiral trans-cyclopropane structure as a γ-aminobutyric acid (GABA) transporter inhibitor selective for GABA transporter (GAT) subtypes GAT-3 and BGT-1 (betaine/GABA transporter-1). Further conformational restriction of 3 with the rigid bicyclo[3.1.0]hexane backbone led to the successful development of the first highly potent and selective BGT-1 inhibitor 4 (IC50 = 0.59 μM). The bioactive conformation of 3 for BGT-1 was also identified.
19
Knud Erik Andersen, Frederik C. Groenwald, A. JOERGENSEN et al. · Journal of Medicinal Chemistry · 1993 · 151 citations
Satoshi Shuto, Shizuka Ono, Yukako Hase et al. · The Journal of Organic Chemistry · 1996 · 98 citations
GABA transporters as drug targets for modulation of GABAergic activity
Arne Schousboe, Alan Sarup, Orla M. Larsson et al. · Biochemical Pharmacology · 2004 · 96 citations
Medicine, Neurobiology, Pharmacology +16
Tsutomu Morikawa, Sasaki Hirofumi, Ryo Hanai et al. · The Journal of Organic Chemistry · 1994 · 89 citations
H. Steve White, William P. Watson, Suzanne L. Hansen et al. · Journal of Pharmacology and Experimental Therapeutics · 2005 · 80 citations
Medicine, Neuroscience, Pharmacology +17